AED President & CEO Brian P. McGuire Issues Statement on 2024 Presidential Results

Nov 07, 2024

Associated Equipment Distributors (AED) President & CEO Brian P. McGuire issued the following statement on the 2024 Presidential Election results.

"Congratulations to President-Elect Donald J. Trump on a successful, hard-fought campaign. AED looks forward to collaborating with the Trump administration and the next Congress to advance our pro-growth, job-creating policy agenda."

"Our country stands at a crossroads where bipartisan cooperation is not just necessary—it is essential. We must rise above gridlock and inaction. Together, Republicans and Democrats have the responsibility to maintain a tax code that fosters growth, to invest in our infrastructure and rural communities, and maintaining and nurturing the next generation of skilled workers who will shape our future. The prosperity of the United States depends on these commitments, and AED members are ready to play a key role in building, feeding, and fueling the country. Now is the time for our elected leaders to set aside partisan divides, prioritize these critical issues, and work hand in hand for the success and future of our nation."

Click here to see more...

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.